Multiple Myeloma

Derek C. Galligan, MD, discusses unmet needs in high-risk multiple myeloma.

Sarah Nagle, MD, discusses the evolution of daratumumab administration in multiple myeloma.

In our exclusive interview, Saad Z. Usmani, MD, FACP, discusses the FDA approval of daratumumab, carfilzomib, and dexamethasone in relapsed/refractory multiple myeloma.

Single-agent daratumumab as maintenance therapy improved progression-free survival compared with observation in patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant.

Parameswaran Hari, MD, MRCP, discusses key data that has read out in relapsed/refractory multiple myeloma, exciting agents generating excitement, and the role of minimal residual disease.

Derek C. Galligan, MD, discusses transplant eligibility in determining subsequent treatment for patients with multiple myeloma.

Sarah Nagle, MD, discusses sequencing challenges in multiple myeloma.

The United Kingdom’s National Institute for Health and Care Excellence has recommended isatuximab-irfc in combination with pomalidomide and dexamethasone as a treatment option for select patients with relapsed/refractory multiple myeloma.

Rebecca Silbermann, MD, MMS, discusses the phase 3 CASTOR trial in relapsed/refractory multiple myeloma.

Data from a subgroup analysis of the phase 2 GRIFFIN study demonstrated that adding daratumumab to lenalidomide, bortezomib, and dexamethasone improved depth of response, stringent complete response, and minimal residual disease negativity, in Black patients with newly diagnosed multiple myeloma.

Sarah Nagle, MD, spotlights the critical role of targeted therapy in multiple myeloma.

Derek C. Galligan, MD, discusses the utility of up-front high-intensity therapy for patients with multiple myeloma.

Rebecca Silbermann, MD, MMS, discusses the role of disease biology in multiple myeloma. 

Rebecca Silbermann, MD, MMS, discusses combinations featuring the monoclonal antibodies daratumumab or isatuximab-irfc and how they have made notable differences in outcomes for patients with relapsed/refractory multiple myeloma.

SpringWorks Therapeutics’ investigational gamma secretase inhibitor, nirogacestat is slated to be evaluated in combination with Janssen Biotech, Inc.’s BCMA- and CD3-targeted bispecific antibody, teclistamab in a phase 1 study in patients with relapsed/refractory multiple myeloma.

Derek Galligan, MD, discusses the role of 3-drug combinations and ongoing research efforts that are focused on evaluating the use of quadruplet regimens earlier on in the treatment journey.

David H. Vesole, MD, PhD, discusses the importance of developing off-the-shelf CAR T-cell therapy ​products in multiple myeloma.

Sagar Lonial, MD, FACP, discusses the development of bispecific T-cell engagers (BiTEs) and CAR T-cell therapy in multiple myeloma.

David H. Vesole, MD, PhD, discusses the advantages of CAR T-cell therapy in multiple myeloma.

Rebecca Silbermann, MD, MMS, discusses current treatment options for fit patients with multiple myeloma who experience early relapse.

Sanjay V. Patel, MD, FRCOphth, discusses the corneal-associated toxicities that can occur with belantamab mafodotin and the need for multidisciplinary management to optimally administer this agent.

Nina Shah, MD, and Sandy Wong, MD, discuss the predictive value of minimal residual disease and a potential course of treatment for a patient with revised International Staging System I multiple myeloma.

David H. Vesole, MD, PhD, discusses the evolution of multiple myeloma treatment, and explained how other BCMA-therapies are poised to impact clinical practice.

Shaily Shah, MD, discusses disease and treatment-related ocular toxicities that can arise in patients with cancer, specific management strategies for patients receiving belantamab mafodotin who develop ocular toxicities, and the importance of collaborative management of these patients.

Elisabet E. Manasanch, MD, discusses novel BCMA-targeted modalities that are emerging in relapsed/refractory multiple myeloma.

Sagar Lonial, MD, FACP, discusses the approval of belantamab mafodotin-blmf and how it addressed an unmet need in relapsed/refractory multiple myeloma.

Kelly Godby, MD, discusses novel triplet combinations and how they are leading the key developments made in the treatment of patients with relapsed/refractory multiple myeloma in recent years.

The FDA has granted a priority review designation to a biologics license application for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma who have received at least 3 previous therapies.

Susan Bal, MD, discusses key trials in the multiple myeloma space.

Thomas G. Martin, MD, discusses the importance of targeted therapy in multiple myeloma, in addition to ongoing research.